Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EBT (2016 - 2025)

Cytokinetics (CYTK) has disclosed EBT for 16 consecutive years, with -$233.5 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT changed N/A to -$233.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$681.8 million, a N/A change, with the full-year FY2025 number at -$657.8 million, down 14.62% from a year prior.
  • EBT was -$233.5 million for Q4 2025 at Cytokinetics, down from -$155.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$13.7 million in Q2 2022 to a low of -$233.5 million in Q4 2025.
  • A 5-year average of -$110.9 million and a median of -$129.4 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 6173.01% in 2021, then surged 76.76% in 2022.
  • Cytokinetics' EBT stood at -$25.9 million in 2021, then plummeted by 417.27% to -$134.1 million in 2022, then dropped by 0.37% to -$134.6 million in 2023, then fell by 11.25% to -$149.7 million in 2024, then crashed by 55.96% to -$233.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's EBT are -$233.5 million (Q4 2025), -$155.6 million (Q1 2025), and -$149.7 million (Q3 2024).